Konstantin Adamsky

Direktor/Vorstandsmitglied bei FILAMENT HEALTH CORP.

53 Jahre

Health Technology

Consumer Services

Aktive Positionen von Konstantin Adamsky

Unternehmen	Position	Beginn	Ende
FILAMENT HEALTH CORP.	Direktor/Vorstandsmitglied	23.08.2022	-
FILAMENT HEALTH CORP.	Independent Dir/Board Member	23.08.2022	-

Unternehmen	Position	Beginn	Ende
Regenera Pharma Ltd. Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel.	Vorstandsvorsitzender	-	01.08.2017
	Geschäftsführer	01.08.2017	01.10.2020
Levco Pharmaceuticals Ltd.	Geschäftsführer	-	-

Weizmann Institute of Science

Doctorate Degree

International

Israel	4
Kanada	2

Operativ

Sektoral

Health Technology	3
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
FILAMENT HEALTH CORP.	Health Technology

Private Unternehmen	2
Regenera Pharma Ltd. Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel.	Health Technology
Levco Pharmaceuticals Ltd.

Private Unternehmen

Health Technology

Levco Pharmaceuticals Ltd.